Back to search
FDAFDA · Food and drugs·Recall number D-0474-2022

Dologen (acetaminophen 325 mg and dexbrompheniramine maleate 1mg) caplets, packaged in a) 90-count bottles, b) 2-count packets, Manufactured in the USA for Kramer-Novis, San Juan, Puerto Rico 00917, NDC 52083-482-02

Published February 9, 2022 · Recall initiated: January 24, 2022

Summary

FDA records drug Class II recall D-0474-2022, published February 9, 2022 and initiated January 24, 2022. Recalling firm: Ultra Seal Corporation; Status: Terminated; Reported quantity: a) 9,060 bottles, b) 44,700 packets; Lot: Lot #: a) 19G074, 19G075, Exp. Date 07/2022; b) 19G075, Exp. Date 07/2022. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

cGMP deviations

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Ultra Seal Corporation
Distributor
Nationwide within the United States
Lot
Lot #: a) 19G074, 19G075, Exp. Date 07/2022; b) 19G075, Exp. Date 07/2022
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Dologen (acetaminophen 325 mg and dexbrompheniramine maleate 1mg) caplets, packaged in a) 90-count bottles, b) 2-count packets, Manufactured in the USA for Kramer-Novis, San Juan, Puerto Rico 00917, NDC 52083-482-02 recalled?

Yes. FDA published recall D-0474-2022 on February 9, 2022. Reported hazard: cGMP deviations

What should I do if I have this product?

Voluntary: Firm initiated · Letter